Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Working Capital Changes (2020 - 2025)

Vivos Therapeutics' Other Working Capital Changes history spans 6 years, with the latest figure at -$440000.0 for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$440000.0 for Q4 2025, down 397.3% from a year ago — trailing twelve months through Dec 2025 was -$514000.0 (down 407.78% YoY), and the annual figure for FY2025 was -$514000.0, down 407.78%.
  • Other Working Capital Changes for Q4 2025 was -$440000.0 at Vivos Therapeutics, down from -$7000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.1 million in Q2 2021 to a low of -$803000.0 in Q3 2021.
  • The 5-year median for Other Working Capital Changes is -$16000.0 (2023), against an average of -$1700.0.
  • Peak annual rise in Other Working Capital Changes hit 24557.83% in 2021, while the deepest fall reached 22468.42% in 2021.
  • Year by year, Other Working Capital Changes stood at $352000.0 in 2021, then tumbled by 187.5% to -$308000.0 in 2022, then skyrocketed by 285.06% to $570000.0 in 2023, then tumbled by 74.04% to $148000.0 in 2024, then crashed by 397.3% to -$440000.0 in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$440000.0, -$7000.0, and $332000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.